CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 135 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,599,435 | +35.5% | 375,549 | -0.5% | 0.00% | 0.0% |
| Q2 2023 | $4,133,483 | +1085.6% | 377,487 | +844.2% | 0.00% | – |
| Q1 2023 | $348,634 | +40.0% | 39,981 | +0.6% | 0.00% | – |
| Q4 2022 | $249,063 | +146.6% | 39,723 | +38.0% | 0.00% | – |
| Q3 2022 | $101,000 | +17.4% | 28,781 | -1.2% | 0.00% | – |
| Q2 2022 | $86,000 | -90.0% | 29,136 | -89.5% | 0.00% | – |
| Q1 2022 | $861,000 | 0.0% | 276,766 | +8.6% | 0.00% | – |
| Q4 2021 | $861,000 | -5.5% | 254,805 | +2.0% | 0.00% | – |
| Q3 2021 | $911,000 | -13.3% | 249,796 | +3.6% | 0.00% | – |
| Q2 2021 | $1,051,000 | -16.3% | 241,012 | -12.8% | 0.00% | – |
| Q1 2021 | $1,255,000 | -21.3% | 276,420 | -0.6% | 0.00% | – |
| Q4 2020 | $1,595,000 | -10.7% | 277,996 | +12.7% | 0.00% | – |
| Q3 2020 | $1,786,000 | +90.8% | 246,630 | -8.0% | 0.00% | – |
| Q2 2020 | $936,000 | +123.4% | 268,155 | -5.3% | 0.00% | – |
| Q1 2020 | $419,000 | -24.0% | 283,137 | +0.8% | 0.00% | – |
| Q4 2019 | $551,000 | -59.3% | 280,984 | +6.2% | 0.00% | – |
| Q3 2019 | $1,355,000 | -30.2% | 264,681 | -2.5% | 0.00% | -100.0% |
| Q2 2019 | $1,942,000 | -43.3% | 271,365 | +5.1% | 0.00% | 0.0% |
| Q1 2019 | $3,428,000 | +75.9% | 258,172 | +4.3% | 0.00% | 0.0% |
| Q4 2018 | $1,949,000 | -32.2% | 247,585 | -4.5% | 0.00% | 0.0% |
| Q3 2018 | $2,873,000 | -11.7% | 259,311 | +6.9% | 0.00% | 0.0% |
| Q2 2018 | $3,254,000 | +95.0% | 242,507 | +88.7% | 0.00% | – |
| Q1 2018 | $1,669,000 | +24.5% | 128,506 | -11.8% | 0.00% | – |
| Q4 2017 | $1,341,000 | +7.2% | 145,723 | -6.1% | 0.00% | – |
| Q3 2017 | $1,251,000 | +1151.0% | 155,174 | +794.7% | 0.00% | – |
| Q2 2017 | $100,000 | +35.1% | 17,344 | +0.8% | 0.00% | – |
| Q1 2017 | $74,000 | +146.7% | 17,204 | 0.0% | 0.00% | – |
| Q4 2016 | $30,000 | -14.3% | 17,204 | -5.9% | 0.00% | – |
| Q3 2016 | $35,000 | -7.9% | 18,283 | -16.4% | 0.00% | – |
| Q2 2016 | $38,000 | +31.0% | 21,879 | +2.3% | 0.00% | – |
| Q1 2016 | $29,000 | -21.6% | 21,379 | -3.5% | 0.00% | – |
| Q4 2015 | $37,000 | -36.2% | 22,147 | -25.9% | 0.00% | – |
| Q3 2015 | $58,000 | – | 29,875 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,254,502 | $20,741,000 | 14.54% |
| Versant Venture Management, LLC | 1,048,601 | $9,647,127,000 | 10.15% |
| Abingworth LLP | 1,147,077 | $10,553,000 | 7.65% |
| Omega Fund Management, LLC | 551,477 | $5,074,000 | 3.67% |
| Opaleye Management Inc. | 665,000 | $6,118,000 | 1.96% |
| DAFNA Capital Management LLC | 361,164 | $3,323,000 | 1.79% |
| Boxer Capital, LLC | 1,012,986 | $9,319,000 | 1.70% |
| Foresite Capital Management III, LLC | 600,000 | $5,520,000 | 1.55% |
| NEXTHERA CAPITAL LP | 536,568 | $4,936,000 | 0.91% |
| Perceptive Advisors | 2,685,882 | $24,710,000 | 0.82% |